---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-103616"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:26:25.670126+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# IN8bio announces positive preclinical data for nsCAR platform and launches INB-330 program at AACR 2023

## Summary
- nsCAR platform showed ability to target cancer cells while sparing healthy tissue; ns19CAR killed 80% of leukemia cells vs 5% of healthy B cells.
- Launched INB-330 program targeting CD33 in AML; ns33CAR demonstrated anti-leukemic activity against AML, B-ALL, and CML cell lines.
- Data presented at AACR Annual Meeting 2023; management highlights potential to address previously 'undruggable' targets.
- Company seeks potential partners for further evaluation of nsCAR platform with additional targets.

## SEC filing metadata
- accession: 0001193125-23-103616
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523103616/0001193125-23-103616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523103616/d465225d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-103616
- JSON: https://secwatch.observer/filing/0001193125-23-103616.json
- Plain text: https://secwatch.observer/filing/0001193125-23-103616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.